FEB 25, 2018 12:54 PM PST

Switching Off Celiac Disease

WRITTEN BY: Carmen Leitch

While gluten-free foods seem like a food trend to some, for others they are a medical necessity. Gluten triggers symptoms in people with celiac disease, an autoimmune disorder impacting around one in 100 people. In those with the disorder, gluten causes an overactive immune response after being modified in the small intestine by an enzyme called TG2, transglutaminase 2. Reporting in the Journal of Biological Chemistry, the researchers have discovered another enzyme that can inactivate TG2, and may help create celiac disease therapeutics.  

People with celiac disease cannot have wheat, which will trigger their symptoms. / Image credit: Pexels

"Currently, therapies to treat people with celiac disease are lacking. The best approach right now is just a strict adherence to a lifelong gluten-free diet," explained the study leader, Michael Yi, a chemical engineering graduate student at Stanford University. "Perhaps the reason behind this is our relatively poor understanding of TG2."

While it’s well known that gluten and TG2 interact to cause an immune response, and their interaction has been investigated, there are unanswered questions, like what TG2 does in the intestines of healthy people.

The director of Stanford Chemistry, Engineering & Medicine for Human Health, Professor Chaitan Khosla, oversaw the new work and has already led several studies indicating that TG2 is either active or inactive, depending on whether a disulfide bond in the enzyme is formed or broken.

"Though there's a lot of transglutaminase 2 protein in the (small intestine), it's all inactive," Khosla explained. "When it became clear that even though the protein was abundant, its activity was nonexistent in a healthy organ, the question became 'What turns the protein on, and then what turns the protein off?'" Several years ago, Khosla's team found the enzyme that breaks the disulfide bond, activating TG2. Now, the researchers conducted experiments that identified the enzyme that recreates that bond and turns off TG2 - ERp57. That enzyme has been understood to help fold cellular proteins inside of cells. But when it inactivates TG2, it functions outside of cells, raising other questions.

"Nobody really understands how (Erp57) gets outside the cell," Khosla noted. "The general thinking is that it's exported from the cell in small quantities; this particular observation suggests that it actually does have a biological role outside the cell."

Now, TG2 is the first protein we know of with a reversible disulfide bond that acts as an on/off switch. "This is a very different kind of on-and-off chemistry than the kind that medicinal chemists would (typically) use," Khosla explained.

Now the team is building on their findings; they want to know if any FDA approved drugs already exist that can act on this switch. Previous work has suggested that low levels of TG2 don’t harm mice. Stopping TG2 may be a way to treat those with celiac disease, so they don’t have to follow a restrictive diet forever.


Sources: AAAS/Eurekalert! Via American Society for Biochemistry and Molecular Biology, Journal of Biological Chemistry

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
DEC 10, 2019
Genetics & Genomics
DEC 10, 2019
The Fallout From the CRISPR Infant Experiment Continues
Last year, Chinese scientist He Jiankui caused tremendous controversy in the scientific world by conducting a gene-editing experiment on humans....
DEC 10, 2019
DEC 10, 2019
T Cell Subset Uniquely Equipped to Target IBD
A specialized form of T cell emerges as a new focus for gastrointestinal health research, specifically in the context of inflammatory bowel disease (IBD) f...
DEC 12, 2019
Cell & Molecular Biology
DEC 12, 2019
Newly Identified Small Proteins Could Have a Big Impact
While the human genome has been sequenced, there are plenty of parts of it that we don't know much about....
DEC 29, 2019
Cell & Molecular Biology
DEC 29, 2019
How close are we to a simple blood test for Parkinson's Disease?
Parkinson’s Disease (PD) alters nerve cells in the brain that produce the neurotransmitter dopamine. Famously regarded as the “happiness”...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
FEB 03, 2020
FEB 03, 2020
The Switch Controlling the Stage of a Common Parasite
The parasite Toxoplasma gondii is thought to infect from one-quarter to one-third of the global population....
Loading Comments...